Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematologic malignancies: Initial Results from multi-institutional first-in-human trials

Rita Assi, Amer Beitinjaneh, Emily Hopewell et al. Nov 03, 2025 pp. 5947-5947 10.1182/blood-2025-5947

Abstract Background CD4 is expressed across several hematopoietic malignancies, including T-cell malignancies (TCM), chronic myelomonocytic...

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin lymphoma in the United States: A population based cohort study

John Vaughn, Malak Munir, Narendranath Epperla Nov 03, 2025 pp. 6337-6337 10.1182/blood-2025-6337

Abstract Background: Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare indolent B-cell lymphoma that is biologically distinc...

Acquired factor v inhibitor and granulomatosis with polyangiitis: Diagnostic challenges and therapeutic implications

Ankushi Sanghvi, Nawaraj Adhikari, Dhairya Nanavaty et al. Nov 03, 2025 pp. 3090-3090 10.1182/blood-2025-3090

Abstract CASE A 61-year-old man with hypertension and cervical disc herniation presented with four months of bilateral lower-extremity crampi...

Utility of 18F-FDG PET/CT for response assessment in marginal zone lymphomas: Preliminary results of the IELSG44 international study

Luca Ceriani, Stefano Luminari, Anne Ségolène Cottereau et al. Nov 03, 2025 pp. 1810-1810 10.1182/blood-2025-1810

Abstract Background: The role of 18F-fluorodeoxyglucosepositron emission tomography/computed tomography (18F-FDG PET/CT) for staging and res...

TP53 mutations define a high-risk subgroup in pediatric Acute Myeloid Leukemia with distinct molecular and cytogenetic features

Stephanie Sendker, Lina Marie Hoffmeister, Nils Von Neuhoff et al. Nov 03, 2025 pp. 447-447 10.1182/blood-2025-447

Abstract Background Despite advances in risk-adapted therapy, outcomes in relapsed/refractory pediatric AML remains poor. TP53 mutations are...

Outcomes with liposomal daunorubicin/cytarabine – a single-center experience

Jonah Heidel, Rafeh Safdar, Cole Blanford et al. Nov 03, 2025 pp. 6973-6973 10.1182/blood-2025-6973

Abstract Introduction Liposomal daunorubicin/cytarabine (CPX-351) is approved for treating patients with therapy-related acute myeloid leuke...

Characterizing the In Vivo impact of inflammation on Samd9l hematopoietic phenotypes.

Melvin Thomas, Emily Xiong, Tamara Westover et al. Nov 03, 2025 pp. 2055-2055 10.1182/blood-2025-2055

Abstract Germline mutations in SAMD9 (sterile alpha motif domain containing 9) and SAMD9L (sterile alpha motif domain containing 9-like) are...

Bone marrow microenvironment retinoic acid receptor signaling represses multipotential progenitor dependent B cell lymphopoiesis through secretion of resistin

Parash Prasad, Angelo D'Alessandro, Ashley Wellendorf et al. Nov 03, 2025 pp. 1405-1405 10.1182/blood-2025-1405

Abstract Lymphoid reconstitution following hematopoietic stem cell transplantation (HSCT) remains a significant clinical challenge. Incomple...

Plasma-derived VWF/FVIII prophylaxis in children under 6 with VWD: First results from wil-33

Akshat Jain, Cindy Leissinger, Vladimir Vdovin et al. Nov 03, 2025 pp. 4855-4855 10.1182/blood-2025-4855

Abstract Introduction: In patients with von Willebrand disease (VWD) and a history of severe and recurrent bleeding, long-term prophylaxis w...

Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation

Alfonso Molina, Quenton Bubb, Ryan Yee et al. Nov 03, 2025 pp. 2494-2494 10.1182/blood-2025-2494

Abstract Background: Graft-versus-host disease (GVHD) has been a significant barrier to successful myeloablative (MAC) allogeneic hematopoie...

Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia

Annamaria Cesarano, Pooja Gangras, Thac Duong et al. Nov 03, 2025 pp. 4119-4119 10.1182/blood-2025-4119

Abstract Chimeric Antigen Receptor (CAR) T cell therapy in acute myeloid leukemia (AML) has shown modest efficacy to date. Most CAR T cell s...

Clinical significance of earlier CHR achievement and long-term CHR maintenance in polycythemia vera patients treated with ropeginterferon alfa-2b

Sung-Eun Lee, Sung-Soo Yoon, Deok-Hwan Yang et al. Nov 03, 2025 pp. 5598-5598 10.1182/blood-2025-5598

Abstract Background: Polycythemia vera (PV), the most common myeloproliferative neoplasm, is characterized by clonal proliferation of cells...

A novel thiotepa-containing conditioning regimen for haploidentical hematopoietic cell transplantation in pediatric aplastic anemia at high risk of cardiotoxicity

Feng Zhang, Suo Pan, Guanhua Hu et al. Nov 03, 2025 pp. 5977-5977 10.1182/blood-2025-5977

Abstract Background Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) have shown a favorable 10-year overall survival rate...

Construction of a prognostic model for new diffuse large B-cell lymphoma and research on risk factors for secondary central nervous system infiltration

Shuling Hou, juya cui, Tao Wang et al. Nov 03, 2025 pp. 5438-5438 10.1182/blood-2025-5438

Abstract Objective: This study aims to improve the International Prognostic Index (IPI) and enhance the Central Nervous System-International...

Random survival forest improves prediction of overall mortality among DLBCL patients against conventional cox models: A SEER database analysis.

Shrishti Sinha, Junho Song, Asfand Yar Cheema et al. Nov 03, 2025 pp. 7190-7190 10.1182/blood-2025-7190

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) represents the most common non-Hodgkin lymphoma subtype, with heterogeneous outco...

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Alma Habib, Isaiah Boateng, Diana Abbott et al. Nov 03, 2025 pp. 8183-8183 10.1182/blood-2025-8183

Abstract Introduction APL is molecularly characterized by t(15;17)/PML::RARA gene fusion as a disease-initiating event and by recurrent gene...

Effect and mechanism of allopurinol in ALL maintenance therapy: Reducing hepatotoxicity and improving myelosuppression effect via TPMT inhibition and increased DNA-thioguanine levels

Yanping Guan, Xiao-Li Zhang, Jian Wang et al. Nov 03, 2025 pp. 6852-6852 10.1182/blood-2025-6852

Abstract Introduction: 6-Mercaptopurine (6-MP) based-maintenance therapy is essential to cure acute lymphoblastic leukemia (ALL). However, i...

Efficacy and prognosis of pola-R-CHP in CD5-positive DLBCL: Rapid response, long-term survival benefits, and early therapeutic optimization

Jingrui Sui, Lijie Yan, Zhao Peiqi et al. Nov 03, 2025 pp. 1916-1916 10.1182/blood-2025-1916

Abstract Background and Aim: CD5-positive diffuse large B-cell lymphoma (DLBCL) represents an aggressive subtype with pa...

Health care utility and real-world comparison of CAR T-cell therapy versus autologous stem cell transplantation in Relapsed/Refractory diffuse large B-cell lymphoma: A propensity score-matched outcomes analysis

Sujan Niraula, Jai Nagarajan, Krishna Ghimire et al. Nov 03, 2025 pp. 7235-7235 10.1182/blood-2025-7235

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment landscape for relapsed...

In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering (simulated fitusiran) using thrombin generation assay

Sibgha Zaheer, Elizabeth Marquez Casas, Guy Young Nov 03, 2025 pp. 1295-1295 10.1182/blood-2025-1295

Abstract Introduction: Eptacog beta, an FDA approved bypassing agent for the treatment of bleeds in patients with hemophilia A and B with in...

Azacytidine combined with CHOP regimen for the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma

Chunmei Yang, Chao Hu, Juying Wei et al. Nov 03, 2025 pp. 1859-1859 10.1182/blood-2025-1859

Abstract Introduction Angioimmunoblastic T-cell lymphoma (AITL) represents an aggressive malignancy derived from follicu...

Predictors of health-related quality of life in adults with chronic lymphocytic leukemia or small lymphocytic lymphoma

Sara Tinsley-Vance, Richie Reich, Daniel Lastorino et al. Nov 03, 2025 pp. 8108-8108 10.1182/blood-2025-8108

Abstract Introduction: Health-related quality of life (HRQOL) will change for the 20,700 people1 who will be diagnosed with chronic lymphocy...

Synergistic apoptotic effect by the combination of clk inhibitor CTX-712 and BCL-2 inhibitor ABT-199 with or without azacytidine in AML and MDS

Hui Yang, Zhihong Fang, Yue Wei et al. Nov 03, 2025 pp. 3839-3839 10.1182/blood-2025-3839

Abstract Alternative splicing (AS) plays a critical role in myeloid malignancy progression through abmormal expression or mutation of splici...

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu et al. Nov 03, 2025 pp. 7230-7230 10.1182/blood-2025-7230

Abstract Background: CD19 CAR-T cells have changed the treatment landscape for relapsed/refractory non-Hodgkin lymphoma (R/R NHL) offering a...

Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis

Wai Nga Grace Lau, Madhu Bhargavi Chandra, Henri Fero et al. Nov 03, 2025 pp. 7565-7565 10.1182/blood-2025-7565

Abstract Introduction Triplet induction therapy with either daratumumab, lenalidomide, and dexamethasone (D-Rd) or borte...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page